Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Immune Thrombocytopenia

8/9/2015

1 Comment

 
Morris Plains, NJ - Immunomedics, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the Company’s humanized anti-CD20 antibody, for the treatment of immune thrombocytopenia (ITP). In a Phase 1 study,1 low-dose veltuzumab, as a single agent, produced an objective response rate of 55 percemt in 38 response-assessable patients with relapsed ITP, including 11 patients (29 percent) who reported a complete response. 

Read More
1 Comment

Rutgers Research Finds Food That Prevent Overeating

8/4/2015

0 Comments

 
New Brunswick, NJ - The researchers at Rutgers found in a new study  that overindulging especially in high-fat food could be caused not by a lack of fortitude, but by the unmanageable hormonal response triggered by an imbalance in the brain. If a person lacks the willpower to stop over eating, the best way a person can deal with such ordeal is to have a series of strategic fight-back foods ready. These are foods that will keep the cravings of a person at bay and at the same time have their brain satisfied by signaling to the stomach that it is full. Foods that can stop overeating are actually available.

Read More
0 Comments

Merck buys Israeli biopharma firm for $95M

8/4/2015

0 Comments

 
Kenilworth, NJ - According to Eric Strauss of NJBiz, "Merck is acquiring an Israeli biopharmaceutical company for $95 million in cash, the drugmaker announced Tuesday. The Kenilworth-based company’s deal for cCAM Biotherapeutics, which is focused on cancer immunotherapies, could potentially include up to $510 million in milestone payments, it said."

Read More
0 Comments

Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation 

7/27/2015

0 Comments

 
Princeton, NJ - Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. The attachment inhibitor is designed to work differently than entry inhibitors, a current class of drugs that targets co-receptors’ activity or fusion after HIV attaches to the CD4+ host cell. BMS-663068 is thought to work at an earlier point in the replication process to prevent the virus’ initial interaction with immune cells entirely, and thus blocks its entry into the cell.

Read More
0 Comments

BioNJ CEO Summit Will Take It to the Top

7/27/2015

0 Comments

 
Trenton, NJ - Dr. Stephen Ostroff, Acting Commissioner of the Food and Drug Administration (FDA), will serve as the featured luncheon speaker at the 3rd Annual BioNJ CEO Summit, Take It to the Top, scheduled for October 9 at the Bridgewater Marriott. Dr. Ostroff will participate in a fireside chat with Dr. William Hait, Global Head of Research and Development for Janssen, the pharmaceutical companies of Johnson & Johnson, entitled: Expediting Therapies and Cures to the Patients Who Need Them: The Evolving Role of the FDA.

Read More
0 Comments

Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport

7/20/2015

0 Comments

 
Basking Ridge, NJ – According to New Jersey Business Magazine, Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. Clinical improvement may be expected one week after administration of Dysport®.”

Read More
0 Comments

Novartis gets early approval for heart failure drug, a potential blockbuster

7/13/2015

0 Comments

 
Trenton, NJ - According to Tom Bergeron of NJBiz, "Novartis officials were hoping the FDA would give approval for what they hope will be a blockbuster drug for heart failure by the end of the summer. On Tuesday, they got even better news. The U.S. Food & Drug Administration approved Entresto (formerly called LCZ696) six weeks ahead of the priority review action date."

Read More
0 Comments

HINJ: Congress Needs to Fix Flaw in Laws Governing Life-Sciences Patents

7/7/2015

0 Comments

 
Montclair, NJ - NJ Spotlight today published an op-ed authored by Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ) on the subject of patent reform legislation currently pending before the U.S. House of Representatives.

Read More
0 Comments

Crowdsourced Health Data Could Make Drugs Safer

6/22/2015

1 Comment

 
Washington D.C. - The Food and Drug Administration (FDA) has announced a research partnership with PatientsLikeMe, an online patient community, to explore the potential for patient-generated health data to identify dangerous drugs. The FDA already collects data about instances of dangerous drug side effects, called adverse events, though its access to this information is limited to patients who voluntarily report adverse events directly to the FDA and aggregated data from insurers and electronic medical records. FDA hopes this new partnership, which grants it access to 110,000 adverse event reports related to 1,000 different medications from PatientsLikeMe users who voluntarily share their data, will allow for more a detailed understanding of how patients take medicine.

Read More
1 Comment

Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir

6/6/2015

0 Comments

 
Kenilworth, NJ - Merck announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes (GT) 1, 4 or 6 infection. Within 60 days of submission, the FDA will determine whether it will accept for review Merck's application as filed. The company plans to submit additional license applications in the European Union and other markets by the end of 2015.

Read More
0 Comments

Medical Innovation Impact Index Launched at FDU Rothman Institute

5/31/2015

0 Comments

 
Madison, NJ - The Medical Innovation Impact Index (MI3), a new method for evaluating the impact of regulation on medical innovation, has been developed at the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s (FDU) Rothman Institute of Innovation and Entrepreneurship. The inaugural MI3 Alert pertains to new FDA (Food & Drug Administration) draft guidance documents and a Senate proposal for accelerating the approval of certain medical devices.

Read More
0 Comments

Celgene Partners gets on the FDA Fast Track

5/25/2015

0 Comments

 
Bridgewater, NJ - Celgene's expansive approach to partnering continues to bear fruit, as two of the Big Biotech's in-licensed treatments have been added to the FDA's fast-track program, promising a speedy regulatory review as each approaches Phase III.

Read More
0 Comments

Johnson & Johnson to create panel for experimental drugs, reports say

5/17/2015

6 Comments

 
New Brunswick, NJ - According to Craig McCarthy, "Johnson & Johnson will be the first company to seek formal advice on providing experimental drugs to the desperately ill -- or "compassionate use"-- before they are approved, reports say. The New Jersey-based drug company appointed a bioethicist Thursday to create a panel, according to The New York Times, charged with making decisions for patient's request for the trial drugs."

Read More
6 Comments

Medical entrepreneur set to transform FDU and drive Patient-Centered Innovation

4/24/2015

1 Comment

 
Teaneck, NJ – According to Hugh Morley of the Record, “Former medical company executive, Dr. Joseph V. Gulfo doesn't want to fight anymore. And that's good news for Fairleigh Dickinson University.” After two years battling to get a melanoma detection device approved by the U.S. Food and Drug Administration, the former CEO of Mela Sciences is now the FDU's Rothman Institute of Innovation and Entrepreneurship.

Read More
1 Comment

Science, patients driving rare disease drug research surge

4/17/2015

0 Comments

 
Trenton, NJ – According to Linda Johnson of The Associated Press, “The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drug makers but now point the way toward a new era of innovative therapies and big profits. The investments come as researchers harness recent scientific advances, including the mapping of the human genome, sophisticated and affordable genetic tests, and laboratory robots that can screen thousands of compounds per hour in search of the most potent ones.”

Read More
0 Comments
<<Previous
    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619